Inhibitory Effects of Furoquinoline Alkaloids from Melicope confusa and Dictamnus albus against Human Phosphodiesterase 5 (hPDE5A) In Vitro |
Nam Kung-woo
(Jung-San Biotechnology Institute, Natural Products Research Institute, Seoul National University, College of Pharmacy)
Je Kang-Hoon (Natural Products Research Institute, Seoul National University, College of Pharmacy) Shin Young-Jun (Jung-San Biotechnology Institute) Kang Sam Sik (Natural Products Research Institute, Seoul National University, College of Pharmacy) Mar Woongchon (Natural Products Research Institute, Seoul National University, College of Pharmacy) |
1 | Francis, S. H., Bessay, E. P., Kotera, J., Grimes, K. A., Liu, L., Thompson, W. J., and Corbin, J. D., Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J. Biol. Chem., 277, 47581-47587 (2002) DOI ScienceOn |
2 | Hirose, R., Okumura, H., Yoshimatsu, A., Irie, J., Onoda, Y., Nomoto, Y., Takai, H., Ohno, T., and Ichimura, M., KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur. J. Pharmacol., 431, 17-24 (2001) DOI ScienceOn |
3 | Natochin, M. and Artemyev, N. O., An interface of interaction between photoreceptor cGMP phosphodiesterase catalytic subunits and inhibitory gamma subunits. J. Biol. Chem., 271, 19964-19969 (1996) DOI ScienceOn |
4 | Tejada, I. S., Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int. J. Impot. Res., 16, S40-S42 (2004) DOI ScienceOn |
5 | Turbo, I. V., Haik, T. L., McAllister-Lucas, L. M., Burns, F., Francis, S. H., and Corbin, J. D., Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodieaterases. A putative NKXnD motif for cGMP biding. J. Biol. Chem., 271, 22240-22244 (1996) DOI ScienceOn |
6 | Fink, T. L., Francis, S. H., Beasley, A., Grimes, K. A., and Corbin, J. D., Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J. Biol. Chem., 274, 34613-34620 (1999) DOI ScienceOn |
7 | Blount, M. A., Beasley, A., Zoraghi, R., Sekhar, K. R., Bessay, E. P., Francis, S. H., Corbin, J. D., Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol., 66, 144-152 (2004) DOI ScienceOn |
8 | Mehats, C., Andersen, C. B., Filopanti, M., Jin, S. L., and Conti, M., Cyclic nucleotide phosphodieterase and their role in endocrine cell signaling. Trends Endocrinol. Metab., 13, 29-35 (2002) DOI ScienceOn |
9 | Uckert, S., Kuthe, A., Stief, C. G., and Jonas, U., Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol., 19, 14-22 (2001) DOI ScienceOn |
10 | Turko, I. V., Ballard, S. A., Francis, S. H., and Corbin, J. D., Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type5) by sildenafil and related compounds. Mol. Pharmacol., 56, 124-130 (1999) DOI |
11 | Sausbier, M., Schubert, R., Voigt, V., Hirneiss, C., Pfeifer, A., Korth, M., Kleppisch, T., Ruth, P., and Hormann, F., Mechanisms of NO/cGMP-dependent vasorelaxation. Circ. Res., 87, 825-830 (2000) DOI ScienceOn |
12 | Crocker, I. C. and Townley, R. G., Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today (Barc), 35, 519-535 (1999) DOI |
13 | Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H., Gingell, C., Sildenafill: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res., 8, 47-52 (1996) |
14 | Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976) DOI PUBMED ScienceOn |
15 | Rybalkin, S. D., Rybalkina, I. G., SHimizu-Albergine, M., Tang, X. B., and Beavo, J. A., PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO Journal, 223, 469-478 (2003) DOI PUBMED ScienceOn |
16 | Lin, C. S., Chow, S., Lau, A., Tu, R., and Lue, T. F., Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int. J. Impot. Res., 14, 15-24 (2002) DOI ScienceOn |
17 | White, D. G. and Martin, W., Differential control and calciumdependence of production of endothelium- derived relaxing factor and prostacyclin by pig arotic ndothelial cells. Br. J. Pharmacol., 97, 683-690 (1989) DOI ScienceOn |
18 | Chen, Y., Traverse, J. H., Hou, M., Li, Y., Du, R., and Bache, R. J., Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am. J. Physiol. Heart Circ. Physiol., 284, H1513-H1520 (2003) DOI |
19 | Wyatt, T. A., Naftilan, A. J., Francis, S. H., and Corbin, J. D., ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am. J. Physiol., 274, H448-H455 (1998) |
20 | Funayama, S., Tanaka, R., Kumekawa, Y., Noshita, T., Mori, T., Kashiwagura, T., and Murata, K., Rat small intestine muscle relaxation alkaloids from Orixa japonica leaves. Biol. Pharm. Bull., 24, 100-102 (2001) DOI ScienceOn |
21 | Wang, M., Urenjak, J., Fedele, E., and Obrenovitch, T. P., Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP. Biochem. Pharmacol., 67, 1619-1627 (2004) DOI ScienceOn |
22 | Chen, Z., Zhang, J., and Stamler, J. S., Identification of the enzymatic mechanism of mitroglycerin bioactivation. Proc. Natl. Acad. Sci. U.S.A., 99, 8306-8311 (2002) DOI ScienceOn |
23 | Schmit, D., Dent, G., and Rabe, K. F., Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin. Exp. Allergy, 29, 99-109 (1999) |
24 | Lacas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P., and Waldman, S., Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev., 52, 385-414 (2000) |
25 | Kim, D. K., Lee, J. Y., Lee, N., Ryu, D. H., Kim, J. S., Choi, J.Y., Ryu, J. H., Kim, N. H., Im, G. H., Choi, W. S., and Kim, T. K., Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5`-sulfonamide moiety of a phenyl ring. Bioorg. Med. Chem., 9, 3013-3021 (2001) DOI ScienceOn |